The use of the normal tissue non-complication probability (NTCP0) in the safety evaluations as a new alternative of assessing the side-effects of the radiation oncology treatments.


Journal

International journal of radiation biology
ISSN: 1362-3095
Titre abrégé: Int J Radiat Biol
Pays: England
ID NLM: 8809243

Informations de publication

Date de publication:
2023
Historique:
pubmed: 6 8 2022
medline: 25 3 2023
entrez: 5 8 2022
Statut: ppublish

Résumé

To encourage the use of the NTCP0 for evaluating safety as a new alternative of assessing the S-Es of the radiation oncology treatments; and the use of the 'NTCP0cal' methodology that calculates/estimates NTCP0. Revisions of studies related to use of the NTCP in the evaluations of S-Es. Development of the first version of the Matlab application of our methodology, which provides three options, two of them employ the well-known aspects of a phenomenological model, or the relationship with the TNTCP; where NTCP0 = 100%-TNTCP; and the third option determines NTCP0 from an assumed NTCP discrete probabilistic distribution from the binomial distribution, where one of its parameters is automatically defined from a databased of the Disease locations Vs. Late complications. As result of revisions of some QUANTEC studies, we can say that: (1) The majority of current NTCP models are DVH-based; (2) The risk of toxicity is the way of evaluating the S-Es of the radiation oncology treatments; and (3) The NTCP are used mainly for evaluations of individual or principal complications or Endpoints of the radiation treatments. The 'NTCP0cal' Matlab application developed in this study has three calculation options. Two of the options provide additional graphical information about the distributions. The NTCP0 is a new radiobiological concept, its introduction let to correct some current P + and UTCP formulations, and will allow evaluating S-Es in whatever activity involving ionizing radiation, like radiation treatments; and its phenomenological model function of dose prescribed (D = n*d) will allow calculating values of NTCP0 for a range of dose per fraction (d) in a treatment with a determined number of fractions (n), or for range of

Identifiants

pubmed: 35930494
doi: 10.1080/09553002.2022.2110299
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

656-662

Auteurs

Terman Frometa-Castillo (T)

Owner at Statistical models project, LLC, Chicago, IL, USA.

Anil Pyakuryal (A)

Division of Science and Mathematics, University of District of Columbia, Washington, DC, USA.

Ganesh Narayanasamy (G)

Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Amadeo Wals-Zurita (A)

Hospital Universitario Virgen Macarena, Sevilla, Spain.

Asghar Mesbahi (A)

Tabriz University of Medical Sciences, Tabriz, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH